CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 89 enrolled
Drug / intervention
Iodinated Contrast Agent +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05036083
NCT05036083N/ACompleted
CompareCT.gov

Added Value of Contrast Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion to a Tertiary Cancer Center

M.D. Anderson Cancer Center·interventional·Posted Sep 5, 2021·Updated Sep 17, 2025

In Brief

A clinical study evaluating Contrast-Enhanced Mammography, Digital Tomosynthesis Mammography, and 2 other interventions for Breast Carcinoma and Invasive Breast Carcinoma. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This clinical trial investigates contrast-enhanced mammography (CEM) in detecting breast cancer. CEM is similar to standard mammography, but it includes an injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. Diagnostic procedures, such as CEM, may increase the chance of finding breast cancers and decrease the risk of having unnecessary biopsies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Carcinoma, Invasive Breast Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 5, 2021
Enrollment StartMar 19, 2021
Primary CompletionMar 25, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.8 years ago

Interventions

Contrast-Enhanced Mammographyprocedure

Undergo CEM

Digital Tomosynthesis Mammographyprocedure

Undergo DBT

Electronic Health Record Reviewother

Medical records reviewed

Iodinated Contrast Agentdrug

Given IV